Novasep has bolstered its upstream processing capabilities by acquiring Henogen, a Belgium-based CMO that has biotech development and cGMP manufacturing expertise.
Northern Irish pack testing specialist Sepha has moved forward with plans to enter the Japanese market, showcasing its BlisterScan platform at Interphex Japan in Tokyo last week.
The USP is revising monographs of four pharmaceutical excipients in light of hazards associated with diethylene glycol contamination and is seeking comments from interested parties.
US CRO Charles River (CRL) has unveiled a raft of executive changes and plans to restructure its PCS unit to provide customers with a more centralised approach to global drug development.
Medidata has followed up its successful IPO by inking a deal with Roche, which is reported to be pulling out of PhRMA and the ABPI, to provide the Swiss pharma with an enterprise-wide electronic EDC system.
The Spanish Ministry of Health is leading a €60m ($84.9m) programme that will build the country’s first vaccine production facility and use Novavax’s recombinant virus-like-particle (VLP) technology.
Dow Chemical is closing three US manufacturing plants, including an ethylene production unit in Hahnville, Louisiana in a further bid to restructure its specialty chemicals business.
UK contracting group Pharmaceutical Development Services (PDS) has set up an office in North Carolina, US to court North America pharma firms for the European development sector.
Sanofi-Aventis has moved to defend its long-acting diabetes treatment Lantus (insulin glargine) and says that recent research linking it to the development of cancer is of “poor quality.”
Altus Pharmaceuticals has terminated its contract with Lonza over an alleged breach in the agreement to provide active pharmaceutical ingredients (API) for Trizytek (liprotamase).
Particle Sciences (PSI) is aiming to advance its contract processing offering by collaborating with Microfluidics and sharing formulation and nanotechnology expertise.
Teva plans to acquire oncology drugs that fail late-stage clinical trials and collaborate with Optimata to "efficiently rescue" the therapeutics and gain regulatory approval.
Rottapharm is investing €7m ($9.8m) in its Irish manufacturing operations, which will create 35 jobs and add 2000 sq m housing three manufacturing and associated packaging lines.
US group Thermo Fisher Scientific and industrial engineering giant Siemens have teamed up to offer the pharmaceutical industry a new way of assessing processes used during early drug development, manufacturing scale up and commercial production.
Outsourcing-Pharma presents its latest round up of movements in the pharmaceutical outsourcing sector, including appointments at WuXi, OctoPlus and Catalent.
US raw materials supplier Originates has boosted its pharmaceutical bovine hide gelatin manufacturing capacity with the addition of two new ISO 9000/9001 certified, GMP-standard production facilities in South America.
Rising demand in China has led to Toray Fine Chemicals (TFC) establishing a joint venture to produce dimethylsulfoxide (DMSO), a reaction solvent in pharma production.
Mylan has followed Teva’s lead by partnering to develop follow-on biologics (FOB), with the Indian generic maker regarding Biocon as the “ideal partner” to help it enter the market.
US CRO PPD has abandoned plans to move into a 40,000 sq ft office building in North Carolina’s Kannapolis biotech complex due to slower than expected development.
Chinese CROs Sundia MediTech, Huiyuan Biotechnology and Frontage Laboratories are the first companies grated express customs clearance privileges under new government pro outsourcing rules.
Quotient Bioresearch has agreed to acquire Amersham Radiolabelling Services and construct a new facility, expanding its radiochemical synthesis, testing and clinical studies offering.
US Marshals have seized products from Caraco’s facilities in Michigan because of concerns over cGMP compliance, which has led to Sun Pharma withdrawing its financial guidance.
Researchers have used nanoparticles to stabilise membrane proteins, allowing for detailed analysis of their structure and molecular functions that could help drug discovery.
US contract services firm KBI Biopharma has begun using the PER.C6 platform for cell line generation as part of its offering to meet growing demand for biomanufacturing services.
Merz is hoping to further its Alzheimer’s research by licensing DiaGenic’s biomarkers for a transitional stage of disease, which is “very important” for stratification of clinical trials.
KV Pharmaceutical found deficiencies and instances of noncompliance during its internal investigation, which was launched in response to issues with the FDA and allegations of management misconduct.
in-PharmaTechnologist presents its latest round up of appointments in the pharmaceutical sector, including Lilly’s CEO taking a role at Nike and Takeda’s illustrious global advisory board.
Sanyo Biomedical and Environmental Solutions claims the H202 steralisation approach used by its Steisonic CxP MCO-19AIC(UVH) cell incubator system is an industry first and effective replacement for ethylene oxide (EtO).
Perceptive Informatics has launched an integrated eClinical suite, which it believes streamlines workflow and allows users to access data across multiple technologies throughout trials.
US contractor Azopharma has added new GMP quality cytotoxics and high-potency manufacturing capacity at its facility in Hollywood, South Florida in a bid to strengthen its position in the trial materials sector.
The world pharma packaging market is predicted to rise 5.3 per cent to more than $47bn (€33.3bn) in 2013, with increased use of biologics driving change.
Synteract will open an office in Prague in the Czech Republic, joining the growing number of CROs to offer sponsors access to treatment naive populations in Central and Eastern Europe (CEE).
Sigpack Systems, a subsidiary of Bosch Packaging Technology, claims its new toploader unit will both improve the efficiency and cut the cost of handling delicate pharmaceutical packaging.
Swiss drugmaker Helsinn has unveiled plans to add high-potency API R&D and manufacturing capacity to its facility in Biasca in the south of the country.
Outsourcing-Pharma presents its latest round up of movements in the pharmaceutical outsourcing sector, including appointments at WuXi, Dishman and Sartorius Stedim.
Emisphere has entered into a research agreement with Syracuse University, which will combine their respective oral drug delivery technologies to enhance absorption of an appetite-suppressing hormone.
Medidata has launched a programme to encourage interoperability and data sharing across clinical trial technologies, which should help cope with the complexity of modern research.
The growth of the Chinese vaccine market is set to outstrip the country’s pharma sector, according to a Frost & Sullivan (F&S) report that predicts 14-15 per cent CAGR.
The number of pharma employees in New Jersey, US fell by 1,400 in 2008, with R&D expenditure, capital investment and product trials also declining, according to a report.
US laboratory group Rules-Based Medicine (RBM) is aiming to improve the utility and reproducibility of biomarker analysis in drug discovery with its new DiscoveryMAP 1.0 offering.
Millipore has ramped up capacity for its Mobius range of single use bio-processing and manufacturing technologies with a new purpose built production facility in Danvers, Massachusetts.
German aseptic filling specialist Vetter has boosted packaging operations at its new facility in Ravensburg to meet growing demand for cost-effective secondary packaging services
Excel Life Sciences (ELS) and PFC Pharma Focus have launched a joint venture in India in response to growing client demand for services in the country delivered by established and proven providers.
Physicians say a lack of information about candidate drugs often prevents them referring patients for clinical trials, according to a new survey by sector analysts CenterWatch.
Automation expenditures in pharma manufacturing are predicted to reach $3bn (€2.15bn) by 2012 because companies must invest in the current “adapt or die” environment, according to a report.
